| 84,54 Euro | -0,053 -0,06 % | ||
| WKN: 920657 ISIN: FR0000120578 Ticker-Symbol: SNW | Frankfurt | 17.05.13 | 17:21 Uhr |
Branche PharmaAktienmarkt CAC-40EURONEXT-100 EURO STOXX 50 STOXX Europe 50 |
|
|
Barclays Research hat die Einstufung von Sanofi vor Zahlen auf "Overweight" mit einem Kursziel von 69,00 Euro belassen. Das erste Quartal dürfte für den Pharmakonzern vergleichsweise positiv ausfallen, schrieb Analyst Mark Purcell in einer Studie vom Montag. Die Zulassungen verschiedener Generika seien auf das Gesamtjahr hochgerechnet worden - dabei kämen Generika für das wichtige Arzneimittel Plavix aber erst ab Mai auf den US-Markt.
AFA0050 2012-04-23/15:20
ISIN: FR0000120578
| Zeit | Aktuelle Nachrichten | |
|---|---|---|
| 17.05. | Sanofi, French Government at Odds Over Fate of Toulouse Site | |
Mehr lesen zu: Sanofi, French Government at Odds Over Fate of Toulouse Site | ||
| 17.05. | Sanofi (SNY) Reports JAKARTA Met Primary Endpoint in Both Groups | |
Mehr lesen zu: Sanofi (SNY) Reports JAKARTA Met Primary Endpoint in Both Groups | ||
| 17.05. | Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis | |
| PARIS, May 17, 2013 /PRNewswire/ --Sanofi (EURONEXT: SANand NYSE: SNY) announced today that the pivotal study, JAKARTA, examining the selective JAK2 inhibitor SAR302503 for myelofibrosis (MF), met... Mehr lesen zu: Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis | ||
| 17.05. | Sanofi's Abnormal Blood Cell Production Inhibitor Meets Goal In Phase III | |
| PARIS (dpa-AFX) - French drugmaker Sanofi (SNY, SNYNF.PK) Friday announced
that the Phase III study of Myelofibrosis inhibitor SAR302503 recorded greater
35 percent reduction in spleen volume... Mehr lesen zu: Sanofi's Abnormal Blood Cell Production Inhibitor Meets Goal In Phase III | ||
| 17.05. | Sanofi:Pivotal PhaseIII JAKARTA Study Meets Primary Endpoint In Both Dose Groups | |
| PARIS (dpa-AFX) - French drugmaker Sanofi (SNY, SNYNF.PK) announced that the
pivotal study, JAKARTA, examining the selective JAK2 inhibitor SAR302503 for
myelofibrosis or MF, met its primary... Mehr lesen zu: Sanofi:Pivotal PhaseIII JAKARTA Study Meets Primary Endpoint In Both Dose Groups |
